Camillo Porta
Responsabile di servizio

Richiedi appuntamento
  • Adjuvant therapy in renal cell carcinoma. Massari F, Di Nunno V, Ciccarese C, Graham J, Porta C, Comito F, Cubelli M, Iacovelli R, Heng DYC.
    Cancer Treat Rev. 2017 Nov;60:152-157. doi: 10.1016/j.ctrv.2017.09.004. Epub 2017 Sep 23. Review.
  • Onco-nephrology: a decalogue. Cosmai L, Porta C, Gallieni M, Perazella MA. Nephrol Dial Transplant. 2016 Apr;31(4):515-9. doi: 10.1093/ndt/gfv320. Epub 2015 Sep 3. Review.
  • Sorafenib in advanced hepatocellular carcinoma. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group.
    N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
  • Glomerular diseases and cancer: evaluation of underlying malignancy. Pani A, Porta C, Cosmai L, Melis P, Floris M, Piras D, Gallieni M, Rosner M, Ponticelli C. J Nephrol. 2016 Apr;29(2):143-152. doi: 10.1007/s40620-015-0234-9. Epub 2015 Oct 26. Review.
  • Renal toxicity of anticancer agents targeting HER2 and EGFR. Cosmai L, Gallieni M, Porta C. J Nephrol. 2015 Dec;28(6):647-57. doi: 10.1007/s40620-015-0226-9. Epub 2015 Sep 4. Review.
  • Targeting PI3K/Akt/mTOR Signaling in Cancer. Porta C, Paglino C, Mosca A. Front Oncol. 2014 Apr 14;4:64. doi: 10.3389/fonc.2014.00064. eCollection 2014. Review.
  • Renal effects of targeted anticancer therapies. Porta C, Cosmai L, Gallieni M, Pedrazzoli P, Malberti F. Nat Rev Nephrol. 2015 Jun;11(6):354-70. doi: 10.1038/nrneph.2015.15. Epub 2015 Mar 3. Review.
  • Choosing the right cell line for renal cell cancer research. Brodaczewska KK, Szczylik C, Fiedorowicz M, Porta C, Czarnecka AM. Mol Cancer. 2016 Dec 19;15(1):83. Review.
  • CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas. Dufies M, Giuliano S, Viotti J, Borchiellini D, Cooley LS, Ambrosetti D, Guyot M, Ndiaye PD, Parola J, Claren A, Schiappa R, Gal J, Frangeul A, Jacquel A, Cassuto O, Grépin R, Auberger P, Bikfalvi A, Milano G, Escudier B, Rioux-Leclercq N, Porta C, Negrier S, Chamorey E, Ferrero JM, Pagès G. Br J Cancer. 2017 Sep 26;117(7):947-953. doi: 10.1038/bjc.2017.276. Epub 2017 Aug 29.
  • Editorial Comment from Dr Porta et al. to Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA. Porta C, Cosmai L, Previtali P. Int J Urol. 2017 Apr;24(4):279-280. doi: 10.1111/iju.13351. No abstract available.

Altre pubblicazioni al seguente LINK

 

Presta servizio in queste sedi

Profili simili